eMedicine Specialties > General Surgery > Lymphatic System

Lymphedema

Author: Don R Revis Jr, MD, Consulting Staff, Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Florida College of Medicine
Contributor Information and Disclosures

Updated: Sep 29, 2009

Introduction

Lymphedema is a notoriously debilitating progressive condition with no known cure. The unfortunate patient faces a lifelong struggle of medical, and sometimes surgical, treatment fraught with potentially lethal complications.

The underlying problem is lymphatic dysfunction, resulting in an abnormal accumulation of interstitial fluid containing high molecular weight proteins. This condition underscores the tremendous importance of a normally functioning lymphatic system, which returns proteins, lipids, and accompanying water from the interstitium to the venous circulation near the subclavian vein–internal jugular vein junction, bilaterally. (See images below and Images 1-2.)

The body quadrants of superficial lymph drainage.

The body quadrants of superficial lymph drainage.

The body quadrants of superficial lymph drainage.

The body quadrants of superficial lymph drainage.



(1) Normal lymphatic flow in (a) deep systems and...

(1) Normal lymphatic flow in (a) deep systems and (b) superficial systems. Note the small collateral vessels interconnecting the 2 systems. (2) Lymphedema develops from obstruction, dilation of valves, valvular insufficiency, and subsequent reversal of lymphatic flow.

(1) Normal lymphatic flow in (a) deep systems and...

(1) Normal lymphatic flow in (a) deep systems and (b) superficial systems. Note the small collateral vessels interconnecting the 2 systems. (2) Lymphedema develops from obstruction, dilation of valves, valvular insufficiency, and subsequent reversal of lymphatic flow.

Frequency

  • In the United States, the highest incidence of lymphedema is observed following breast cancer surgery, particularly among those who undergo radiation therapy following axillary lymphadenectomy. Among this population, 10-40% develop some degree of ipsilateral upper extremity lymphedema.
  • Worldwide, 140-250 million cases of lymphedema are estimated to exist, with filariasis being the most common cause.

Etiology

Lymphedema may be classified1 as primary or secondary, based on underlying etiology. However, this classification usually has little significance in determining treatment modality.

  • Primary lymphedema represents a developmental abnormality of the lymphatic system.
    • Primary lymphedema has been further subdivided into 3 forms, including congenital lymphedema, lymphedema praecox, and lymphedema tarda, depending on age at presentation. These conditions are most often sporadic, with no family history, and involve the lower extremity almost exclusively.
    • All 3 forms of primary lymphedema likely originate from a developmental abnormality that is present, but not always clinically evident, at birth. Some cases may become evident later in life when a triggering event or worsening of the condition causes the lymphatic transport capacity to exceed the volume of interstitial fluid formation, causing the patient to be unable to maintain normal lymphatic flow.
    • Congenital lymphedema represents all forms that are clinically evident at birth and accounts for 10-25% of all primary lymphedema cases. Females are affected twice as often as males, and the lower extremity is involved 3 times more frequently than the upper extremity. Two thirds of patients have bilateral lymphedema, and this form may improve spontaneously with increasing age.
      • A subset of patients with congenital lymphedema has a familial sex-linked pattern of inheritance, which is termed Milroy disease. It accounts for 2% of primary lymphedema cases.
      • The histology of the lymphatic channels often demonstrates an anaplastic pattern without subcutaneous lymphatic trunks but with normal dermal plexus.
    • Lymphedema praecox is the most common form of primary lymphedema. By definition, it becomes clinically evident after birth and before age 35 years. This condition accounts for 65-80% of all primary lymphedema cases and most often arises during puberty. Females are affected 4 times as often as males. About 70% of cases are unilateral, with the left lower extremity being involved more often than the right. Histologically, these patients are likely to demonstrate a hypoplastic pattern, with the lymphatics reduced in caliber and number.
    • Lymphedema tarda, also known as Meige disease, does not become clinically evident until age 35 years or older. As the rarest form of primary lymphedema, it accounts for only 10% of cases. Histologically, patients are likely to demonstrate a hyperplastic pattern, with tortuous lymphatics increased in caliber and number. They often display absent or incompetent valves.
  • Secondary lymphedema represents an acquired dysfunction of otherwise normal lymphatics.
    • Secondary lymphedema has an identifiable cause that destroys or renders inadequate the otherwise normal lymphatics.
    • In the United States, it commonly results from damage or removal of regional lymph nodes through surgery, radiation, infection, or tumor invasion or compression.
    • Worldwide, the most common cause is filariasis, the direct infestation of lymph nodes by the parasite Wuchereria bancrofti.2
    • Other causes include vein stripping, peripheral vascular surgery, lipectomy, burns, burn scar excision, and insect bites.

Pathophysiology

The normal function of the lymphatics is to return proteins, lipids, and water from the interstitium to the intravascular space; 40-50% of serum proteins are transported by this route each day. High hydrostatic pressures in arterial capillaries force proteinaceous fluid into the interstitium, resulting in increased interstitial oncotic pressure that draws in additional water.

Interstitial fluid normally contributes to the nourishment of tissues. About 90% of the fluid returns to the circulation via entry into venous capillaries. The remaining 10% is composed of high molecular weight proteins and their oncotically associated water, which are too large to readily pass through venous capillary walls. This leads to flow into the lymphatic capillaries where pressures are typically subatmospheric and can accommodate the large size of the proteins and their accompanying water. The proteins then travel as lymph through numerous filtering lymph nodes on their way to join the venous circulation.

In a diseased state, the lymphatic transport capacity is reduced. This causes the normal volume of interstitial fluid formation to exceed the rate of lymphatic return, resulting in the stagnation of high molecular weight proteins in the interstitium. It usually occurs after flow has been reduced by 80% or more. The result, as compared to other forms of edema that have much lower concentrations of protein, is high-protein edema, or lymphedema, with protein concentrations of 1.0-5.5 g/mL. This high oncotic pressure in the interstitium favors the accumulation of additional water.

Accumulation of interstitial fluid leads to massive dilatation of the remaining outflow tracts and valvular incompetence that causes reversal of flow from subcutaneous tissues into the dermal plexus. The lymphatic walls undergo fibrosis, and fibrinoid thrombi accumulate within the lumen, obliterating much of the remaining lymph channels. Spontaneous lymphovenous shunts may form. Lymph nodes harden and shrink, losing their normal architecture.

In the interstitium, protein and fluid accumulation initiates a marked inflammatory reaction. Macrophage activity is increased, resulting in destruction of elastic fibers and production of fibrosclerotic tissue. Fibroblasts migrate into the interstitium and deposit collagen. The result of this inflammatory reaction is a change from the initial pitting edema to the brawny nonpitting edema characteristic of lymphedema. Consequently, local immunologic surveillance is suppressed, and chronic infections, as well as malignant degeneration to lymphangiosarcoma, may occur.

The overlying skin becomes thickened and displays the typical peau d'orange (orange skin) appearance of congested dermal lymphatics. The epidermis forms thick scaly deposits of keratinized debris and may display a warty verrucosis. Cracks and furrows often develop and accommodate debris and bacteria, leading to lymphorrhea, the leakage of lymph onto the surface of the skin.

Presentation

Patients present with varying degrees of severity, from mild swelling to severe disabling enlargement with potentially life-threatening complications. This disease is often first noticed by the patient as an asymmetry or increased circumference of an extremity. As swelling slowly progresses, patients may have difficulty fitting into clothing. Once well established, lymphedema may cause fatigue related to the size and weight of the extremity, embarrassment in public, and severe impairment of daily activities. Recurrent bacterial or fungal infections are also common.

The diagnosis is usually made with a thorough history and physical examination. Other causes of edema, such as edema secondary to congestive heart failure, renal insufficiency, hepatic insufficiency, or venous stasis disease, must be excluded. Malignancy must always be considered, particularly when patients report sudden onset, rapid progression, or associated pain. These symptoms may indicate direct tumor growth or metastatic disease in the regional lymph node basin.

Indications

Surgical treatment is palliative, not curative, and it does not obviate the need for continued medical therapy. Moreover, it is rarely indicated as the primary treatment modality. Rather, reserve surgical treatment for those who do not improve with conservative measures or in cases where the extremity is so large that it impairs daily activities and prevents successful conservative management.

Relevant Anatomy

Before embarking on the treatment of lymphedema, a thorough knowledge of the relevant anatomy is essential. Blind-ended lymphatic capillaries arise within the interstitial spaces of the dermal papillae. These unvalved superficial dermal lymphatics drain into interconnected subdermal channels, which parallel the superficial venous system. These subsequently drain into the deeper, epifascial system of valved trunks lined with smooth muscle cells and located just above the deep fascia of the extremity. This system is responsible for the drainage of lymph from the skin and subcutaneous tissues. Valves provide for unidirectional flow towards regional lymph nodes and eventually the venous circulation in the neck. Flow is achieved by variations of tissue pressure through skeletal muscle contractions, pulsatile blood flow, and contractions of the spiral smooth muscle fibers surrounding larger lymphatic channels.

A deeper valved subfascial system of lymphatics is responsible for the drainage of lymph from the fascia, muscles, joints, ligaments, periosteum, and bone. This subfascial system parallels the deep venous system of the extremity. The epifascial and subfascial systems normally function independently, although valved connections do exist in the popliteal, inguinal, antecubital, and axillary regions where lymph nodes form interconnected chains. These connections probably do not function under normal conditions; however, in lymphedema, some reversed flow through perforators from the epifascial to the subfascial system may occur as a mechanism of decompression of the epifascial system. In lymphedema, the derangement is almost always exclusive to the epifascial lymphatic system, with the subfascial system being uninvolved. This is the basis for the surgical approaches to lymphedema, which focus on the epifascial system.

Contraindications

Contraindications to intermittent pneumatic pump compression therapy include congestive heart failure, deep vein thrombosis, and active infection.

More on Lymphedema

Overview: Lymphedema
Workup: Lymphedema
Treatment: Lymphedema
Follow-up: Lymphedema
Multimedia: Lymphedema
References
Further Reading

References

  1. Gasbarro V, Michelini S, Antignani PL, et al. The CEAP-L classification for lymphedemas of the limbs: the Italian experience. Int Angiol. Aug 2009;28(4):315-24. [Medline].

  2. Srivastava PK, Dhillon GP. Elimination of lymphatic filariasis in India--a successful endeavour. J Indian Med Assoc. Oct 2008;106(10):673-4, 676-7. [Medline].

  3. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. Aug 13 2009;361(7):664-73. [Medline].

  4. Mayrovitz HN. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol. 2009;7(2):101-8. [Medline].

  5. Salgado CJ, Sassu P, Gharb BB, et al. Radical reduction of upper extremity lymphedema with preservation of perforators. Ann Plast Surg. Sep 2009;63(2):302-6. [Medline].

  6. van der Walt JC, Perks TJ, Zeeman BJ, et al. Modified Charles procedure using negative pressure dressings for primary lymphedema: a functional assessment. Ann Plast Surg. Jun 2009;62(6):669-75. [Medline].

  7. Brennan MJ, Miller LT. Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Cancer. Dec 15 1998;83(12 Suppl American):2821-7. [Medline].

  8. Candeira M, Schuch W, Greiner L, Buckley L, Gold H, Langer A, et al. American Cancer Society Lymphedema Workshop: Workgroup V: Collaboration and advocacy. Cancer. Dec 15 1998;DA - 19990128(12 Suppl American):2888-90. [Medline].

  9. Child AH, Beninson J, Sarfarazi M. Cause of primary congenital lymphedema. Angiology. Apr 1999;50(4):325-6. [Medline].

  10. Foldi E. The treatment of lymphedema. Cancer. Dec 15 1998;83(12 Suppl American):2833-4. [Medline].

  11. Fonkalsrud EW. Congenital malformations of the lymphatic system. Semin Pediatr Surg. May 1994;3(2):62-9. [Medline].

  12. Garfein ES, Borud LJ, Warren AG, Slavin SA. Learning from a lymphedema clinic: an algorithm for the management of localized swelling. Plast Reconstr Surg. Feb 2008;121(2):521-8. [Medline].

  13. Gerber LH. A review of measures of lymphedema. Cancer. Dec 15 1998;83(12 Suppl American):2803-4. [Medline].

  14. Jeffs E. Management of chronic oedema. J Wound Care. Oct 1998;7(9 Suppl):1-4. [Medline].

  15. Kim DI, Huh S, Hwang JH, Kim YI, Lee BB. Venous dynamics in leg lymphedema. Lymphology. Mar 1999;32(1):11-4. [Medline].

  16. Leitch AM, Meek AG, Smith RA, Boris M, Bourgeois P, Higgins S, et al. American Cancer Society Lymphedema Workshop. Workgroup I: Treatment of the axilla with surgery and radiation--preoperative and postoperative risk assessment. Cancer. Dec 15 1998;DA - 19990128(12 Suppl American):2877-9. [Medline].

  17. Mortimer PS. The pathophysiology of lymphedema. Cancer. Dec 15 1998;83(12 Suppl American):2798-802. [Medline].

  18. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ. 1997;75(6):491-503. [Medline].

  19. Rajan TV, Gundlapalli AV. Lymphatic filariasis. Chem Immunol. 1997;66:125-58. [Medline].

  20. Rinehart-Ayres ME. Conservative approaches to lymphedema treatment. Cancer. Dec 15 1998;83(12 Suppl American):2828-32. [Medline].

  21. Rockson SG. Precipitating factors in lymphedema: myths and realities. Cancer. Dec 15 1998;83(12 Suppl American):2814-6. [Medline].

  22. Rockson SG, Miller LT, Senie R, Brennan MJ, Casley-Smith JR, Földi E, et al. American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer. Dec 15 1998;DA - 19990128(12 Suppl American):2882-5. [Medline].

  23. Runowicz CD. Lymphedema: patient and provider education: current status and future trends. Cancer. Dec 15 1998;83(12 Suppl American):2874-6. [Medline].

  24. Shimony A, Tidhar D. Lymphedema: a comprehensive review. Ann Plast Surg. Feb 2008;60(2):228. [Medline].

  25. Thiadens SR. Current status of education and treatment resources for lymphedema. Cancer. Dec 15 1998;83(12 Suppl American):2864-8. [Medline].

  26. Walley DR, Augustine E, Saslow D, Bailey S, Jeffs E, Lasinski B, et al. American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources--professional education and availability of patient services. Cancer. Dec 15 1998;DA - 19990128(12 Suppl American):2886-7. [Medline].

Keywords

lymphedema, lymphoedema, lymphedema treatment, lymphedema therapy, filariasis, lymphatic filariasis, lymphedema compression, lymphedema pump, lymphatic dysfunction, accumulation of interstitial fluid containing high molecular weight proteins, lymphatic system, breast cancer surgery, axillary lymphadenectomy, primary lymphedema, congenital lymphedema, lymphedema praecox, lymphedema tarda, Milroy disease, Meige disease, Meige's disease, secondary lymphedema

Contributor Information and Disclosures

Author

Don R Revis Jr, MD, Consulting Staff, Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Florida College of Medicine
Don R Revis Jr, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Society for Aesthetic Plastic Surgery, and American Society of Plastic Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Amy L Friedman, MD, Professor of Surgery, Director of Transplantation, State University of New York Upstate Medical University College of Medicine, Syracuse
Amy L Friedman, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Medical Women's Association, American Society for Artificial Internal Organs, American Society of Transplant Surgeons, American Society of Transplantation, Association for Academic Surgery, Association of Women Surgeons, International College of Surgeons, International Liver Transplantation Society, New York Academy of Sciences, Pennsylvania Medical Society, Philadelphia County Medical Society, Society of Critical Care Medicine, and Transplantation Society
Disclosure: Nothing to disclose.

CME Editor

Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice
Michael E Zevitz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Chief Editor

John Geibel, MD, DSc, MA, Vice Chairman, Professor, Department of Surgery, Section of Gastrointestinal Medicine and Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director of Surgical Research, Department of Surgery, Yale-New Haven Hospital
John Geibel, MD, DSc, MA is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, and Society for Surgery of the Alimentary Tract
Disclosure: AMGEN Royalty Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.